Navin Pinto
机构: University of Colorado Anschutz Medical Campus
每年引用次数
引用次数
引用: 3,290
H-指数: 24
I10-指数 : 41
出版物: 132
Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer
Lorena Lazo De La Vega , Hannah Comeau , Sarah Sallan , Alyaa Al-Ibraheemi
JCO Precision Oncology 6
8
2022
Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.
Alanna J Church , Laura Corson , Pei-Chi Kao , Alma Imamovic-Tuco
Journal of Clinical Oncology 39 ( 15_suppl) 10005 -10005
3
2021
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
Thomas Cash , Araz Marachelian , Steven G DuBois , Yueh-Yun Chi
Journal of Clinical Oncology 40 ( 16_suppl) 10038 -10038
2
2022
Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.
Susan N Chi , Franck Bourdeaut , Michela Casanova , Lindsay Baker Kilburn
Journal of Clinical Oncology 40 ( 16_suppl) 10040 -10040
11
2022
Computer-assisted Curie scoring for metaiodobenzylguanidine (mIBG) scans in patients with neuroblastoma.
Elizabeth Sokol , Roger Engelmann , Navin R Pinto , Adam Starkey
Journal of Clinical Oncology 34 10559 -10559
2016
Pulmonary alveolar proteinosis in an 8 year-old female with systemic onset juvenile idiopathic arthritis: A case report.
Navin R Pinto , Karen B Onel , Charles Spencer , Oren J Lakser
ARTHRITIS AND RHEUMATISM 54 ( 9) S505 -S505
2006
Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.
Bradley DeNardo , Jennie Foster , Navin R Pinto , Giselle Linda Saulnier Sholler
Journal of Clinical Oncology 40 ( 16_suppl) e22015 -e22015
2022
STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.
Catherine Michelle Albert , Navin R Pinto , Mallory Taylor , Ashley Wilson
Journal of Clinical Oncology 40 ( 16_suppl) 2541 -2541
10
2022
EGFR as a target in pediatric solid tumors
Catherine M Albert , Navin R Pinto , Erin R Rudzinski , Julie R Park
CANCER RESEARCH 80 ( 14) 113 -113
2020
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
Navin R Pinto , Catherine Michelle Albert , Mallory Taylor , Ashley Wilson
Journal of Clinical Oncology 40 ( 16_suppl) 10011 -10011
15
2022
ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.
Catherine Michelle Albert , Navin R Pinto , Mallory Taylor , Ashley Wilson
Journal of Clinical Oncology 41 ( 16_suppl) TPS11581 -TPS11581
1
2023
Abstract CT137: ENLIGHTen-01: a phase 1 study of fluorescein-specific (FITC-E2)-car T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma
Catherine M Albert , Navin R Pinto , Mallory Taylor , Ashley Wilson
Cancer Research 83 ( 8_Supplement) CT137 -CT137
2023
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
Navin R Pinto , Catherine Michelle Albert , Mallory Taylor , Ashley Wilson
Journal of Clinical Oncology 41 ( 16_suppl) 10043 -10043
2023
Neonatal appendicitis presenting as a painless abdominal mass
Anurekha G Hall , Jeffrey P Otjen , Nicholas A Vitanza , Kimberly J Riehle
Journal of Pediatric Surgery Case Reports 72 101964 -101964
1
2021
Predictors of differential outcomes according to response to induction chemotherapy in high-risk neuroblastoma.
Elizabeth Sokol , Brian LaBarre , Arlene Naranjo , Navin R Pinto
Journal of Clinical Oncology 40 ( 16_suppl) 10032 -10032
2022
Molecular Targeted Therapy of Pediatric Neoplasms
Elizabeth A Sokol , Navin R Pinto
Precision Molecular Pathology of Neoplastic Pediatric Diseases 67 -86
2018
Outcome in patients with refractory high-risk neuroblastoma.
Amir Bari Siddiqui , Akosua Oppong , Cindy Yuan , Guimin Gao
Journal of Clinical Oncology 38 ( 15_suppl) 10537 -10537
2020
Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
Susan N Chi , Franck Bourdeaut , Theodore Willis Laetsch , Maryam Fouladi
Journal of Clinical Oncology 38 ( 15_suppl) 10525 -10525
3
2020
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.
Birgit Geoerger , Hyoung Jin Kang , Michal Yalon-Oren , Lynley V Marshall
Journal of Clinical Oncology 35 10525 -10525
9
2017
KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.
Birgit Geoerger , Hyoung Jin Kang , Michal Yalon-Oren , Lynley V Marshall
Journal of Clinical Oncology 36 10525 -10525
10
2018